The Dropout Problem in Ketamine Therapy
A new clinical analysis published in Psychiatric Times is drawing fresh attention to an uncomfortable reality in ketamine treatment for treatment-resistant depression (TRD): a meaningful number of patients stop before they see full benefit. The review examines side effect profiles and discontinuation rates across NMDA receptor antagonists—primarily IV ketamine and intranasal esketamine (Spravato)—and makes a case for faster, more data-driven clinical decision-making. Clinicians are being urged to optimize doses sooner, switch agents when necessary, and track outcomes systematically using tools like the PHQ-9.
For people using oral ketamine tablets, this conversation is directly relevant—even though tablets are not the primary focus of the research. Understanding why patients discontinue, and how route of administration influences that decision, can help tablet users and their providers make smarter choices from the start.
What the Side Effect Data Actually Shows
NMDA antagonists share a recognizable side effect cluster: dissociation, dizziness, nausea, elevated blood pressure, and sedation. The severity and duration of these effects vary significantly based on dose, formulation, and how quickly the drug reaches peak plasma concentration—a metric known as Tmax. IV ketamine, which delivers the drug rapidly into the bloodstream, tends to produce the most intense dissociative episodes. Intranasal esketamine follows a faster absorption curve than oral routes but with somewhat lower peak intensity than IV.
Oral ketamine tablets occupy a distinctly different pharmacokinetic territory. Absorption through the gastrointestinal tract is slower and less complete than nasal or intravenous delivery—bioavailability for oral ketamine typically ranges from 16–20%, compared to roughly 45% for intranasal and near 100% for IV. This slower rise to peak plasma levels generally translates to a milder, more gradual onset of dissociation and psychoactive effects. For many patients, particularly those who found IV or intranasal side effects intolerable, this is precisely why they end up on tablets.
The tradeoff is potency: the antidepressant signal from oral ketamine is real but may require more consistent dosing cadence to accumulate therapeutic benefit. This is why the clinical call to optimize doses quickly—rather than lingering at a subtherapeutic level for weeks—applies with particular force to tablet-based regimens.
Discontinuation: A Signal Worth Reading
The Psychiatric Times analysis highlights that discontinuation is not always a treatment failure—sometimes it reflects appropriate clinical pivoting. A patient who stops esketamine due to persistent nausea or intolerable dissociation and transitions to oral ketamine is not dropping out; they are finding a better-fitting modality. The problem flagged by clinicians is premature discontinuation: stopping before an adequate dose has been reached or before enough time has elapsed to judge efficacy.
For oral tablet users, this distinction matters. Tablets tend to have a longer ramp-up period because of lower bioavailability and the need for consistent, repeated dosing—often sublingual or buccal administration to improve absorption beyond basic GI uptake. Patients who expect the rapid, dramatic shift sometimes reported with IV infusions may abandon tablets prematurely, concluding they aren't working. The research underscores what many ketamine-prescribing clinicians already advise: commit to a structured dosing schedule, track symptom scores at regular intervals, and give the regimen time to work before making changes.
The PHQ-9 tracking recommendation from the review is worth taking seriously. Objective, timestamped symptom scores make it much easier to detect a genuine response that might not feel dramatic in the moment—which is common with gradual oral dosing—and to distinguish a plateau that warrants a dose adjustment from normal early-phase variability.
Key Takeaway for Tablet Users
Oral ketamine's slower absorption curve generally means milder side effects than IV or intranasal routes—but it also means slower onset of antidepressant effect. Don't mistake gradual progress for no progress. Track PHQ-9 scores consistently, communicate side effects to your prescriber early, and resist stopping before reaching an adequate dose. If side effects are significant even with oral tablets, ask your provider whether formulation adjustments (sublingual vs. swallowed, timing, dose frequency) could help before discontinuing entirely.
What This Means for How You Manage Your Treatment
The clinical message embedded in this research is ultimately about pacing and communication. Faster optimization does not mean rushing—it means not letting avoidable delays (underdosing, unaddressed side effects, lack of outcome tracking) extend the time before you reach remission. For patients on oral tablets specifically, a few practical implications stand out.
Sublingual over swallowed when possible. Holding a ketamine tablet under the tongue or against the cheek before swallowing meaningfully increases bioavailability by bypassing first-pass liver metabolism. If your protocol isn't accounting for this, it's worth discussing with your provider.
Side effects are information, not failure. If you're experiencing nausea, dizziness, or cognitive fogginess on your current dose, report it promptly rather than pushing through silently. Dose timing, formulation, and even food intake around dosing can all be adjusted. Discontinuing because of manageable side effects that were never addressed is a preventable outcome.
Compare with your baseline, not with others. Oral ketamine works differently from infusions and troches. Outcomes reported in IV-based studies are not directly applicable. What matters is your own trajectory over time—which is exactly why the PHQ-9 and similar tools are so useful.
The full analysis is available at Psychiatric Times.
Share